Lv3
380 积分 2021-01-26 加入
NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China
2个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
2个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study
2年前
已完结
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
2年前
已完结
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer
2年前
已完结
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
2年前
已完结
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
2年前
已完结
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
2年前
已完结
皖公网安备34019202002308
